Public Sector Pension Investment Board Buys 25,698 Shares of Artivion, Inc. $AORT

Key Points

• The Public Sector Pension Investment Board increased its stake in Artivion, Inc. by 27.4%, owning approximately $2.94 million worth of shares after acquiring an additional 25,698 shares.
• Artivion reported $0.24 EPS for the last quarter, surpassing analysts' expectations of $0.11, with a revenue of $112.97 million, representing a year-over-year increase of 15.3%.
• Recent analyst ratings show a consensus of "Buy" for Artivion, with target prices ranging from $40 to $45 set by multiple firms.

Public Sector Pension Investment Board grew its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 27.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,650 shares of the company's stock after buying an additional 25,698 shares during the quarter. Public Sector Pension Investment Board owned 0.28% of Artivion worth $2,941,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in AORT. Nuveen LLC purchased a new stake in Artivion during the 1st quarter valued at $2,653,000. Invesco Ltd. lifted its holdings in shares of Artivion by 27.9% during the first quarter. Invesco Ltd. now owns 341,656 shares of the company's stock valued at $8,398,000 after purchasing an additional 74,589 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Artivion by 5.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 376,052 shares of the company's stock valued at $9,243,000 after buying an additional 17,860 shares during the last quarter. Natixis Advisors LLC boosted its position in shares of Artivion by 16.4% during the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after buying an additional 1,777 shares during the last quarter. Finally, Thornburg Investment Management Inc. purchased a new position in Artivion in the 1st quarter worth about $3,261,000. Institutional investors own 86.37% of the company's stock.

Analysts Set New Price Targets

AORT has been the subject of a number of research analyst reports. JMP Securities lifted their price target on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. Oppenheimer reissued an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a report on Monday. Needham & Company LLC increased their target price on Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday. Finally, Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Artivion currently has an average rating of "Buy" and a consensus price target of $40.63.

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 12,500 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John E. Davis sold 10,802 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total value of $471,723.34. Following the completion of the sale, the insider owned 208,778 shares of the company's stock, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,538 shares of company stock worth $3,444,651. 8.10% of the stock is owned by insiders.

Artivion Stock Performance

Shares of NYSE AORT traded down $1.30 during trading on Monday, hitting $43.53. The company had a trading volume of 410,754 shares, compared to its average volume of 611,682. The stock has a 50 day simple moving average of $33.95 and a 200 day simple moving average of $28.92. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The firm has a market capitalization of $2.05 billion, a P/E ratio of -103.64 and a beta of 1.64.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to the consensus estimate of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company's revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.